

## Short Communications

ID	Title	Presenting Author
<b>22/05/2025</b>	<b>10.05 - 11.05</b>	<b>HIV 2025: disparities and trajectories</b>
<b>34</b>	Integrating HPV vaccination promotion into community-based sexual health services: an empowerment approach	Marco Stizioli, Brescia
<b>42</b>	Fast track health path: screening, information and care of fragile people in Rome	Paola Sammarco, Roma
<b>148</b>	When Health Services are Hard to Reach: Insights from a mobile HIV/STI programme for migrant sex workers	Chiara Soligo, Milano
<b>278</b>	Poor retention in care among transgender women living with HIV(TWLWH): a call for targeted interventions	Pierluigi Francesco Salvo, Roma
<b>336</b>	STIs Testing Among Young People: Strategies, Results, and Educational Implications	Caterina Pellegris, Chiuduno BG
<b>321</b>	Promoting Hepatitis and HIV screening in high prevalence populations: the 'Test in the City' Project	Ilaria Mercurio, Chiuduno BG
<b>22/05/2025</b>	<b>11.10 - 12.10</b>	<b>ART and comorbidities</b>
<b>15</b>	Management of polypharmacy and potential drug-drug interactions in people with HIV and cancer: insights from a 4-year multidisciplinary clinic experience	Cristina Gervasoni, Milano
<b>272</b>	Neurocognitive impairment over time in people with HIV (PWH) with and without cerebrospinal viral escape (CHVE)	Carmela Pinnetti, Roma
<b>287</b>	Comparison between the Frascati criteria and Equivalent Scores for the neurocognitive assessment (NCA) of people living with HIV (PWH)	Giulia Del Duca, Rome
<b>330</b>	Atherogenic Index of Plasma as a Predictor of Cardiovascular Events in People living with HIV: Evidence from the ICONA Cohort	Nicola Squillace, Monza
<b>194</b>	Critical illness in people with HIV (PWH). Temporal trends, reasons for admission, and mortality of PWH admitted to ICU from 2010 to 2024. The experience of two Italian referral centres	Federica La Fata, Roma
<b>106</b>	Correlation among lipid profile, subclinical atherosclerosis and hepatic steatosis in PLWH: the role of inflammation	Antonietta Boccia, Napoli
<b>22/05/2025</b>	<b>12.15 - 13.15</b>	<b>Open issues in virology and pharmacology</b>
<b>109</b>	Plasma SARS-CoV-2 RNA associates with disease severity during acute infection but not with persistent symptoms	Roberta Rovito, Milano
<b>319</b>	The potential impact of pharmacogenetics on bulevirtide plasma exposure in the clinical setting	Jessica Cusato, Torino
<b>276</b>	Clinical and laboratory parameters correlated to HDV undetectability after 48 weeks of bulevirtide	Andrea Di Lorenzo, Roma
<b>146</b>	Analysis of HIV proviral integration sites in the host genome of PWH with a virus displaying amino acid polymorphism in the integrase C-terminal region	Isabella Abbate, Roma
<b>234</b>	Performance of a Next-generation Sequencing Test for HIV Drug Resistance Analysis in Proviral HIV-DNA	Tiziano Giacomo Alice, Torino
<b>226</b>	Long acting cabotegravir and rilpivirine plasma and intracellular pharmacokinetics in the clinical setting after 2-year follow-up	Micol Ferrara, Torino

## Short Communications

ID	Title	Presenting Author
<b>22/05/2025</b>	<b>15.10 - 16.10</b>	<b>Data that matter: epidemiological realities of HIV in the modern era</b>
<b>17</b>	Incidence of new HIV diagnoses in Italy: a comparison with major Western European countries	Vincenza Regine, Roma
<b>96</b>	Comparison of new HIV diagnosis incidence between Italians and foreigners present in Italy from 2012 to 2023: analysis of the increase post- COVID19 pandemic	Raffaello Iacono, Roma
<b>174</b>	A survey on the continuum of care for HIV in sex-workers in Italy: the contribution of NGOs	Elisabetta Gennaro, Roma
<b>300</b>	HBV and HCV Testing in Italy's Marginalized Groups: Advancing WHO's 2030 Elimination Goal	Teresita Caruso, Pisa
<b>213</b>	Characteristics of people living with HIV who were lost to follow-up	Laura Comi, Bergamo
<b>23</b>	All-Cause Mortality in People with Four-Class Drug-Resistant HIV: A Matched Cohort Analysis with Data from the PRESTIGIO Registry	Andrea Giacomelli, Milano
<b>22/05/2025</b>	<b>16.15 - 17.25</b>	<b>Deep insights in two-drug antiretroviral regimen</b>
<b>40</b>	Comparable dynamics of cell-associated HIV-RNA, total and intact proviral HIV-1 DNA in virologically suppressed people with HIV switching to 2DR or continuing 3DR over a 18-month follow-up	Niccolò Bartolini, Siena
<b>160</b>	Effectiveness of first-line lamivudine-dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort	Alessandra Vergori, Roma
<b>235</b>	Real-world experience with Doravirine in Italy: comparing three-drug and two-drug regimens	Adriana Cervo, Modena
<b>311</b>	Adverse event development in people with HIV on long-acting Cabotegravir + Rilpivirine: timing and clinical insights	Gaia Cologgi, Genova
<b>326</b>	Reasons for declining Long-Acting-Injectable therapy in eligible PLWH: insights from the WHY-Not study	Layla Pagnucco, Pavia
<b>75</b>	Real-World Discontinuation and Virological Outcomes of Long-Acting Cabotegravir + Rilpivirine in virologically suppressed adults living with HIV: A Multicenter Observational Study in Tuscany (LAHIV)	Filippo Lagi, Firenze
<b>169</b>	Durability, Adherence, and Discontinuation of Long-Acting Cabotegravir/Rilpivirine: A 96-Week Real-World Study	Davide Moschese, Milano
<b>23/05/2025</b>	<b>15.05 - 16.05</b>	<b>From epidemiology to innovation: vaccine coverage and viral pathogenesis</b>
<b>41</b>	Implementation of a monitoring system for immunization coverage in people living with HIV in the Lombardy region	Manuel Maffeo, Milano
<b>151</b>	Implementing the National Vaccination Plan in People with HIV (PWH): a national survey among ICONA centers.	Antonio Russo, Napoli
<b>178</b>	Generation of a novel and safe viral-based neutralization assay for monitoring Flavivirus emerging and re-emerging zoonoses	Alessandra Gallinaro, Roma
<b>131</b>	Incidence and Risk Factors of HPV-16 Clearance at the Anal Site in MSM with HIV	Elena Bruzzesi, Milano
<b>93</b>	G-Quadruplexes are Molecular Switches in HIV-1 Latency Regulation	Emanuela Ruggiero, Padova
<b>315</b>	Low-level viremia during antiretroviral treatment is not associated with impaired immunological recovery in the second-generation INSTI era	Tommaso Clemente, Milano



*No boundaries in  
 Infection Research  
 and Care*



## Short Communications

ID	Title	Presenting Author
<b>23/05/2025</b>	<b>15.05 - 16.05</b>	<b>Challenges in prevention</b>
<b>257</b>	Predictors of STI reinfection in a monocentric cohort of high-risk men who have sex with men	Pierluigi Francesco Salvo, Roma
<b>153</b>	Mpox vaccination and natural immunity: a comparative serological study	Donatella Maddalena, Milano
<b>50</b>	Macrolide-resistant Mycoplasma genitalium: epidemiological insights from a clinical study in high-risk populations	Giancarlo Ciaccioli, Milano
<b>119</b>	One-year experience in HIV non-occupational post-exposure prophylaxis (nPEP) management at Jenner 44 STI clinic - Luigi Sacco Hospital, Milan, Italy: focus on adherence	Laura Cordier, Milano
<b>341</b>	Burden of Anal High Grade Dysplasia is High Among an Under-screened Population Such as Women Living With HIV	Eugenio Nelson Cavallari, Roma
<b>339</b>	Is DoxyPEP Being Overused? Insights from a PrEP Clinic Cohort	Francesco Caruso, Milano